Some news yesterday on Roche's anti-TIGIT drug in 1st line NSCLC (PD-L1 high):
https://www.fiercebiotech.com/biotech/strike-2-roche-flunks-another-phase-3-lung-cancer-test-leave-tigit-space-reeling
https://pharmaphorum.com/news/roches-tigit-ambitions-take-another-blow/
Would seem to make IMM's upcoming TACTI data in 1st line NSCLC (PD-L1 all comer) even more important.
Media, page-208
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |